Ad is loading...
EVO
Price
$5.44
Change
+$0.34 (+6.67%)
Updated
Nov 15 closing price
129 days until earnings call
PAHC
Price
$24.46
Change
-$0.44 (-1.77%)
Updated
Nov 15 closing price
79 days until earnings call
Ad is loading...

EVO vs PAHC

Header iconEVO vs PAHC Comparison
Open Charts EVO vs PAHCBanner chart's image
Evotec SE
Price$5.44
Change+$0.34 (+6.67%)
Volume$1.16M
CapitalizationN/A
Phibro Animal Health
Price$24.46
Change-$0.44 (-1.77%)
Volume$197.05K
CapitalizationN/A
EVO vs PAHC Comparison Chart
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EVO vs. PAHC commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Sell and PAHC is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (EVO: $5.44 vs. PAHC: $24.46)
Brand notoriety: EVO and PAHC are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 551% vs. PAHC: 101%
Market capitalization -- EVO: $2.77B vs. PAHC: $523.71M
EVO [@Pharmaceuticals: Other] is valued at $2.77B. PAHC’s [@Pharmaceuticals: Other] market capitalization is $523.71M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whilePAHC’s FA Score has 2 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 2 green, 3 red.
According to our system of comparison, PAHC is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 6 TA indicator(s) are bullish while PAHC’s TA Score has 4 bullish TA indicator(s).

  • EVO’s TA Score: 6 bullish, 3 bearish.
  • PAHC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EVO is a better buy in the short-term than PAHC.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а +31.72% price change this week, while PAHC (@Pharmaceuticals: Other) price change was +2.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.07%. For the same industry, the average monthly price growth was -7.87%, and the average quarterly price growth was -11.90%.

Reported Earning Dates

EVO is expected to report earnings on Mar 27, 2025.

PAHC is expected to report earnings on Feb 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-5.07% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than PAHC($524M). EVO has higher P/E ratio than PAHC: EVO (476.19) vs PAHC (34.11). PAHC YTD gains are higher at: 115.898 vs. EVO (-53.623). PAHC has higher annual earnings (EBITDA): 83.7M vs. EVO (-63.26M). EVO has more cash in the bank: 619M vs. PAHC (92.5M). PAHC has less debt than EVO: PAHC (513M) vs EVO (589M). PAHC has higher revenues than EVO: PAHC (982M) vs EVO (821M).
EVOPAHCEVO / PAHC
Capitalization2.77B524M528%
EBITDA-63.26M83.7M-76%
Gain YTD-53.623115.898-46%
P/E Ratio476.1934.111,396%
Revenue821M982M84%
Total Cash619M92.5M669%
Total Debt589M513M115%
FUNDAMENTALS RATINGS
EVO vs PAHC: Fundamental Ratings
EVO
PAHC
OUTLOOK RATING
1..100
4925
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
9186
PRICE GROWTH RATING
1..100
3637
P/E GROWTH RATING
1..100
26
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (23) in the Pharmaceuticals Major industry is significantly better than the same rating for EVO (98) in the null industry. This means that PAHC’s stock grew significantly faster than EVO’s over the last 12 months.

PAHC's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as EVO (100) in the null industry. This means that PAHC’s stock grew similarly to EVO’s over the last 12 months.

PAHC's SMR Rating (86) in the Pharmaceuticals Major industry is in the same range as EVO (91) in the null industry. This means that PAHC’s stock grew similarly to EVO’s over the last 12 months.

EVO's Price Growth Rating (36) in the null industry is in the same range as PAHC (37) in the Pharmaceuticals Major industry. This means that EVO’s stock grew similarly to PAHC’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is in the same range as PAHC (6) in the Pharmaceuticals Major industry. This means that EVO’s stock grew similarly to PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOPAHC
RSI
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
66%
Bullish Trend 7 days ago
70%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 3 days ago
72%
Aroon
ODDS (%)
Bullish Trend 3 days ago
63%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
EVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PAHC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEYIX9.43-0.01
-0.11%
American Century Equity Income C
IEMGX9.91-0.02
-0.20%
Voya Multi-Manager Emerging Markets Eq I
BCSCX8.00-0.03
-0.37%
BlackRock Commodity Strategies Inv C
PMDIX20.02-0.12
-0.60%
Principal Small-MidCap Dividend Inc Inst
NSFHX12.87-0.12
-0.92%
Natixis Target Retirement 2040 N